Top

Published in:

Open Access 01-12-2012 | Poster presentation

Th17 is involved in the pathogenesis of Bechet's disease via CCL20-CCR6 axis

Authors: Hidekata Yasuoka, Zhu Chen, Tsutomu Takeuchi, Masataka Kuwana

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Excerpt

Behcet's disease (BD) is an autoinflammatory disease with a unique distribution characterized by uveitis, and mucosal and skin lesions, which are characterized by the prominent infiltration of immune cells such as lymphocytes and neutrophils. A novel helper T-cell subset Th17, IL-17-producing helper T cells, has been appreciated [1]. IL-17 is involved in the induction of a series of chemokines, growth factors, proteases, and cytokines, and production of IL-17 results in induction of neutrophil migration and chronic inflammation [2]. Based on these findings, we hypothesized that Th17 is involved in the pathogenesis of BD. …

Park H, Li Z, Yang XO, et al: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005, 6: 1133-1141. 10.1038/ni1261.PubMedCentralCrossRefPubMed

Romagnani S: Human Th18 cells. Arthritis Res Ther. 2008, 10: 206-10.1186/ar2392.PubMedCentralCrossRefPubMed

Title: Th17 is involved in the pathogenesis of Bechet's disease via CCL20-CCR6 axis
Authors: Hidekata Yasuoka
Zhu Chen
Tsutomu Takeuchi
Masataka Kuwana
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar3680

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2012

IL-17, synoviolin and rheumatoid arthritis chronicity

Future direction of pathogenesis and treatment for rheumatic disorders

Reconstruction of injured spinal cord by epigenetic regulation of transplanted neural stem cells

Discrepancy between patient and physician in assessment of global severity in early rheumatoid arthritis

Unc93 homolog B1 restricts systemic lethal inflammation by orchestrating TLR7 and TLR9 response

Synovial fibroblasts display an uncontrolled inflammatory and tissue destructive response to TNF-α

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials